日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
World
Home / World / Americas

Pfizer, Moderna step up testing Omicron-specific vaccines

Xinhua | Updated: 2022-01-29 09:11
Share
Share - WeChat
Pedestrians walk in front of a COVID-19 vaccination site in the Brooklyn borough of New York, the United States, Nov 19, 2021. [Photo/Agencies]

WASHINGTON - Pfizer and Moderna are stepping up trials of COVID-19 vaccines that specifically target the Omicron variant, as the highly contagious variant now accounts for 99.9 percent of new infections in the United States.

Pfizer and its partner BioNTech announced on Tuesday the initiation of a clinical study in up to 1,420 healthy adults aged 18 to 55, to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine candidate.

The study will have three cohorts examining different regimens of the current Pfizer-BioNTech COVID-19 vaccine or an Omicron-based vaccine.

The Omicron-specific vaccine will be administered as a 30-microgram dose, the same as the current vaccine.

"While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," said Kathrin U. Jansen, senior vice president and head of vaccine research and development at Pfizer.

A Pfizer spokesperson told CNN the company has already begun to manufacture this vaccine.

A day later, Moderna also announced it has begun dosing patients in a clinical trial testing its COVID-19 vaccine booster shot that is specific to the Omicron variant.

The Phase 2 study will assess the safety, tolerability and immune response generated by the Omicron-specific shot in adults.

Moderna expects to enroll about 600 adult participants aged 18 and older, split equally between two groups. The first group will include people who received the two-dose vaccine, and the second group will include people who received the two-dose vaccine and the current booster.

Participants in both groups will receive a single dose of the Omicron-specific booster.

Moderna plans to seek authorization from the US Food and Drug Administration for its Omicron-specific COVID-19 vaccine booster by the summer, said Moderna's Chief Medical Officer Paul Burton on Thursday.

The time frame means that the targeted vaccine may not be available to the public until the second half of the year, according to a report of NBC News.

The Omicron-specific booster shots are being developed as the highly transmissible variant strengthens its dominance in this country.

The latest data from the US Centers of Disease Control and Prevention (CDC) show that 99.9 percent of new infection cases in the country are now driven by the Omicron variant.

The Delta variant, which spiked last summer, now only makes up the remaining 0.1 percent.

The new infections driven by Omicron have risen rapidly since early December. The variant accounted for only 0.6 percent of new cases in the week ending Dec 4, rising to 88.9 percent in the week ending Jan 1, and 99.4 percent in the week ending Jan 15, CDC data show.

Although Omicron can evade the antibodies elicited by authorized vaccines, making breakthrough infections more common, current vaccines still provide strong protection against hospitalization and death, several studies have suggested.

Protection against infection and death during the Delta-predominant period and against infection during Omicron emergence were higher among booster vaccine dose recipients, especially among persons aged 50 and older, according to a recent CDC study.

Another CDC study published Thursday suggests a third COVID-19 mRNA vaccine dose provides improved protection against COVID-19-associated hospitalization among immunocompromised adults.

The CDC has recommended everyone aged 12 and older get boosters or an extra dose of COVID-19 vaccine to restore the protection against the Omicron variant.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 五月婷婷一区 | 国产视频1 | 在线观看国产视频 | 插下面视频 | 午夜影院在线看 | jizzjizz日本护士视频 | 深夜福利软件 | 白白操在线视频 | 性色av一区二区三区四区 | 999热在线精品观看全部 | 欧美一级片在线视频 | 久久精品一区二区免费播放 | 特黄特色大片免费高清视频 | 亚洲精品一区二区三区在线看 | 日韩一区二区福利视频 | 久久久亚洲欧洲日产国码606 | 久久夜色精品 | 日韩中文一区二区三区 | 欧美特黄a级高清免费大片 精品日本三级在线观看视频 | 四虎影视在线看免费完整版 | 国产伊人网 | 亚洲精品久久久蜜桃 | 好好的日com| 2015小明看日韩成人免费视频 | www.久草| 狠狠操夜夜爱 | 免费一级毛片在线播放欧美 | 欧美一区二区三区中文字幕 | 日本黄色视屏 | 色噜噜色噜噜天天拍一拍 | 日韩欧美一区二区三区 | 国产午夜永久福利视频在线观看 | 精品日韩欧美国产一区二区 | 成人av免费观看 | 久久精品欧美一区二区三区不卡 | 成年男女男免费视频网站不卡 | 黄色网址免费入口 | 日韩一区二区精品视频 | 精品视频在线观看 | 首页亚洲国产丝袜长腿综合 | 2021中文字幕亚洲精品 |